This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEC180BO_M.jpg
The company also reported a higher number of locations than anticipated, ending with 8,720 locations compared to the estimated 8,689. Additionally, Walgreens saw a significant increase in comparable sales for U.S. Retail Pharmacy – Pharmacy at 9.2%, significantly higher than the estimated 0.6%.
Revenues across various segments showed varied performance against estimates and YoY changes. The U.S. Retail Pharmacy segment generated $21.13 billion, while revenues from the U.S. Retail Pharmacy- Retail and International – Wholesale segments amounted to $6.54 billion and $2.90 billion respectively.
Despite these results, Walgreens is currently ranked #4 (Sell) by Zacks, indicating potential underperformance in the near term. This ranking comes even as its shares returned +3.2% over the past month, outperforming the Zacks S&P 500 composite’s -2.4% change.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
